{
    "1": {
        "reference_id": "25",
        "citation": "Takada et al., Int J Cancer 2021",
        "title": "Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with NSCLC",
        "year": 2021,
        "tags": {
            "treatment": [
                "PD-1/PD-L1 Blockade"
            ],
            "cancer": [
                "NSCLC"
            ],
            "biology": [
                "Gut microbiome composition",
                "Alpha diversity"
            ],
            "intervention": [
                "Probiotics"
            ]
        }
    },
    "2": {
        "reference_id": "2",
        "citation": "Maynard et al., Nature 2012",
        "title": "Reciprocal interactions of the intestinal microbiota and immune system",
        "year": 2012,
        "tags": {
            "treatment": [],
            "cancer": [],
            "biology": [
                "Innate immunity",
                "Adaptive immunity",
                "T cell-microbiota interactions",
                "Immune homeostasis"
            ],
            "intervention": [
                "Review article"
            ]
        }
    },
    "3": {
        "reference_id": "3",
        "citation": "Dzutsev et al., Annu Rev Immunol 2017",
        "title": "Microbes and cancer",
        "year": 2017,
        "tags": {
            "treatment": [],
            "cancer": [
                "General"
            ],
            "biology": [
                "Tumorigenesis",
                "Microbiome-cancer interactions",
                "Inflammation"
            ],
            "intervention": [
                "Review article"
            ]
        }
    },
    "4": {
        "reference_id": "4",
        "citation": "Zheng et al., Cell Res 2020",
        "title": "Interaction between microbiota and immunity in health and disease",
        "year": 2020,
        "tags": {
            "treatment": [],
            "cancer": [],
            "biology": [
                "Immune modulation",
                "Inflammation",
                "Host-microbiota interactions"
            ],
            "intervention": [
                "Review article"
            ]
        }
    },
    "5": {
        "reference_id": "5",
        "citation": "Cullin et al., Cancer Cell 2021",
        "title": "Microbiome and cancer",
        "year": 2021,
        "tags": {
            "treatment": [],
            "cancer": [
                "General"
            ],
            "biology": [
                "Tumor microenvironment",
                "Microbiome-cancer interactions",
                "Immune regulation"
            ],
            "intervention": [
                "Review article"
            ]
        }
    },
    "44": {
        "reference_id": "44",
        "citation": "Han et al., Nat Biomed Eng 2021",
        "title": "Generation of systemic anti-tumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel",
        "year": 2021,
        "tags": {
            "treatment": [
                "PD-1/PD-L1 Blockade"
            ],
            "cancer": [
                "Preclinical tumor models"
            ],
            "biology": [
                "Memory T cells",
                "Microbiome modulation"
            ],
            "intervention": [
                "Prebiotics",
                "Inulin"
            ]
        }
    },
    "46": {
        "reference_id": "46",
        "citation": "Wastyk et al., Cell 2021",
        "title": "Gut-microbiota-targeted diets modulate human immune status",
        "year": 2021,
        "tags": {
            "treatment": [],
            "cancer": [],
            "biology": [
                "Fiber",
                "Fermented foods",
                "Microbial diversity",
                "Inflammatory markers"
            ],
            "intervention": [
                "Diet",
                "High-fiber diet",
                "Fermented food diet"
            ]
        }
    },
    "47": {
        "reference_id": "47",
        "citation": "Huang et al., Gut 2022",
        "title": "Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating anti-PD-1/PD-L1 immunotherapy",
        "year": 2022,
        "tags": {
            "treatment": [
                "PD-1/PD-L1 Blockade"
            ],
            "cancer": [
                "Preclinical tumor models"
            ],
            "biology": [
                "Tryptophan metabolism",
                "Kynurenine pathway",
                "Microbiome modulation"
            ],
            "intervention": [
                "Prebiotics",
                "Polysaccharides"
            ]
        }
    },

{
  "6": {
    "reference_id": "6",
    "citation": "Routy et al., Science 2018",
    "title": "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors",
    "year": 2018,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["NSCLC", "RCC"],
      "biology": ["Akkermansia muciniphila", "Alpha diversity", "FMT validation"],
      "intervention": ["Fecal microbiota transplantation"]
    }
  },
  "8": {
    "reference_id": "8",
    "citation": "Matson et al., Science 2018",
    "title": "The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients",
    "year": 2018,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Melanoma"],
      "biology": ["Bifidobacterium", "Faecalibacterium", "FMT validation"],
      "intervention": ["Fecal microbiota transplantation"]
    }
  },
  "9": {
    "reference_id": "9",
    "citation": "Jin et al., J Thorac Oncol 2019",
    "title": "The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese NSCLC patients",
    "year": 2019,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["NSCLC"],
      "biology": ["Alpha diversity", "Alistipes", "Prevotella"],
      "intervention": []
    }
  },
  "10": {
    "reference_id": "10",
    "citation": "Lee et al., Nat Med 2022",
    "title": "Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Melanoma"],
      "biology": ["Roseburia", "Akkermansia", "Bifidobacterium", "Meta-analysis"],
      "intervention": []
    }
  },
  "11": {
    "reference_id": "11",
    "citation": "Smith et al., Nat Med 2022",
    "title": "Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy",
    "year": 2022,
    "tags": {
      "treatment": ["CAR-T"],
      "cancer": ["B-cell lymphoma"],
      "biology": ["Ruminococcus", "Bacteroides", "Faecalibacterium", "Cytokine release syndrome"],
      "intervention": []
    }
  },
  "12": {
    "reference_id": "12",
    "citation": "Stein-Thoeringer et al., Nat Med 2023",
    "title": "A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy",
    "year": 2023,
    "tags": {
      "treatment": ["CAR-T"],
      "cancer": ["Lymphoma"],
      "biology": ["Akkermansia", "Ruminococcus lactaris", "Alpha diversity"],
      "intervention": ["Antibiotic exposure"]
    }
  },
  "13": {
    "reference_id": "13",
    "citation": "Hu et al., Nat Commun 2022",
    "title": "CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies",
    "year": 2022,
    "tags": {
      "treatment": ["CAR-T"],
      "cancer": ["Hematologic malignancies"],
      "biology": ["Faecalibacterium", "Roseburia", "Cytokine release syndrome"],
      "intervention": []
    }
  },
  "15": {
    "reference_id": "15",
    "citation": "Luu et al., Nat Commun 2021",
    "title": "Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer",
    "year": 2021,
    "tags": {
      "treatment": ["ACT"],
      "cancer": ["Preclinical tumor models"],
      "biology": ["SCFAs", "Butyrate", "CD8+ T cells"],
      "intervention": ["Short-chain fatty acids supplementation"]
    }
  },
  "16": {
    "reference_id": "16",
    "citation": "He et al., Cell Metab 2021",
    "title": "Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity",
    "year": 2021,
    "tags": {
      "treatment": ["Immunotherapy"],
      "cancer": ["Preclinical tumor models"],
      "biology": ["SCFAs", "Microbial metabolites", "CD8+ T cells"],
      "intervention": []
    }
  },
  "18": {
    "reference_id": "18",
    "citation": "Paik et al., Nature 2022",
    "title": "Human gut bacteria produce TH17-modulating bile acid metabolites",
    "year": 2022,
    "tags": {
      "treatment": [],
      "cancer": [],
      "biology": ["Bile acids", "Th17 cells", "Microbial metabolites"],
      "intervention": []
    }
  },
  "19": {
    "reference_id": "19",
    "citation": "Bender et al., Cell 2023",
    "title": "Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment",
    "year": 2023,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Melanoma"],
      "biology": ["Tryptophan metabolism", "Indole derivatives", "Lactobacillus reuteri"],
      "intervention": ["Dietary tryptophan modulation"]
    }
  },
  "20": {
    "reference_id": "20",
    "citation": "Hezaveh et al., Immunity 2022",
    "title": "Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity",
    "year": 2022,
    "tags": {
      "treatment": [],
      "cancer": ["Preclinical tumor models"],
      "biology": ["Tryptophan metabolism", "Aryl hydrocarbon receptor", "Tumor-associated macrophages"],
      "intervention": []
    }
  },
  "23": {
    "reference_id": "23",
    "citation": "McCulloch et al., Nat Med 2022",
    "title": "Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Melanoma"],
      "biology": ["Immune-related adverse events", "Bacteroides", "Microbiome composition"],
      "intervention": []
    }
  },
  "24": {
    "reference_id": "24",
    "citation": "Derosa et al., Nat Med 2022",
    "title": "Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced NSCLC",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["NSCLC"],
      "biology": ["Akkermansia muciniphila", "Antibiotic exposure", "Microbiome composition"],
      "intervention": ["Antibiotics"]
    }
  },
  "26": {
    "reference_id": "26",
    "citation": "Zheng et al., J Immunother Cancer 2019",
    "title": "Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with HCC",
    "year": 2019,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["HCC"],
      "biology": ["Akkermansia", "Ruminococcaceae", "Microbiome composition"],
      "intervention": []
    }
  },
  "27": {
    "reference_id": "27",
    "citation": "Lee et al., J Immunother Cancer 2022",
    "title": "Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable HCC",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["HCC"],
      "biology": ["Microbial metabolites", "Lachnospiraceae", "Metabolomics"],
      "intervention": []
    }
  },
  "28": {
    "reference_id": "28",
    "citation": "Limeta et al., JCI Insight 2020",
    "title": "Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma",
    "year": 2020,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Melanoma"],
      "biology": ["Meta-analysis", "Microbiome composition", "Biomarker discovery"],
      "intervention": []
    }
  },
  "29": {
    "reference_id": "29",
    "citation": "Spencer et al., Science 2021",
    "title": "Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response",
    "year": 2021,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Melanoma"],
      "biology": ["Dietary fiber", "Microbiome diversity", "Immune modulation"],
      "intervention": ["Diet", "Probiotics"]
    }
  },
  "30": {
    "reference_id": "30",
    "citation": "Simpson et al., Nat Med 2022",
    "title": "Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Melanoma"],
      "biology": ["Dietary fiber", "Microbial ecology", "Microbiome composition"],
      "intervention": ["Diet"]
    }
  },
  "31": {
    "reference_id": "31",
    "citation": "Paulos et al., J Clin Invest 2007",
    "title": "Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling",
    "year": 2007,
    "tags": {
      "treatment": ["ACT"],
      "cancer": ["Preclinical tumor models"],
      "biology": ["TLR4 signaling", "LPS", "CD8+ T cells"],
      "intervention": []
    }
  },
  "32": {
    "reference_id": "32",
    "citation": "Uribe-Herranz et al., JCI Insight 2018",
    "title": "Gut microbiota modulates adoptive cell therapy via CD8Î± dendritic cells and IL-12",
    "year": 2018,
    "tags": {
      "treatment": ["ACT"],
      "cancer": ["Preclinical tumor models"],
      "biology": ["Dendritic cells", "IL-12", "Antibiotic exposure"],
      "intervention": ["Vancomycin"]
    }
  },
  "33": {
    "reference_id": "33",
    "citation": "Luu et al., Sci Rep 2018",
    "title": "Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate",
    "year": 2018,
    "tags": {
      "treatment": ["ACT"],
      "cancer": ["Preclinical tumor models"],
      "biology": ["Butyrate", "HDAC inhibition", "CD8+ T cells"],
      "intervention": ["Short-chain fatty acids supplementation"]
    }
  },
  "34": {
    "reference_id": "34",
    "citation": "Yang et al., Oncoimmunology 2021",
    "title": "Blood microbiota diversity determines response of advanced CRC to chemotherapy combined with adoptive T cell immunotherapy",
    "year": 2021,
    "tags": {
      "treatment": ["ACT"],
      "cancer": ["CRC"],
      "biology": ["Blood microbiome", "Bifidobacterium", "Microbial diversity"],
      "intervention": ["Chemotherapy"]
    }
  },
  "37": {
    "reference_id": "37",
    "citation": "Derosa et al., Ann Oncol 2018",
    "title": "Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced RCC and NSCLC",
    "year": 2018,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["RCC", "NSCLC"],
      "biology": ["Microbiome disruption"],
      "intervention": ["Antibiotics"]
    }
  },
  "38": {
    "reference_id": "38",
    "citation": "Wilson et al., Cancer Immunol Immunother 2020",
    "title": "The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis",
    "year": 2020,
    "tags": {
      "treatment": ["ICI"],
      "cancer": ["Multiple cancers"],
      "biology": ["Meta-analysis", "Microbiome disruption"],
      "intervention": ["Antibiotics"]
    }
  },
  "39": {
    "reference_id": "39",
    "citation": "Peiffer et al., Neoplasia 2022",
    "title": "Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic CRPC receiving pembrolizumab",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["Prostate cancer"],
      "biology": ["Microbiome composition", "Treatment response"],
      "intervention": ["Antibiotics"]
    }
  },
  "40": {
    "reference_id": "40",
    "citation": "Elkrief et al., Oncoimmunology 2019",
    "title": "Antibiotics are associated with decreased PFS in advanced melanoma patients treated with ICI",
    "year": 2019,
    "tags": {
      "treatment": ["ICI"],
      "cancer": ["Melanoma"],
      "biology": ["Microbiome disruption", "Progression-free survival"],
      "intervention": ["Antibiotics"]
    }
  },
  "41": {
    "reference_id": "41",
    "citation": "Chalabi et al., Ann Oncol 2020",
    "title": "Efficacy of chemotherapy and atezolizumab in patients with NSCLC receiving antibiotics and PPIs",
    "year": 2020,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["NSCLC"],
      "biology": ["Microbiome disruption"],
      "intervention": ["Proton pump inhibitors", "Antibiotics"]
    }
  },
  "42": {
    "reference_id": "42",
    "citation": "Tomita et al., Oncoimmunology 2022",
    "title": "Clostridium butyricum therapy restores the decreased efficacy of ICI in lung cancer patients receiving PPIs",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["NSCLC"],
      "biology": ["Clostridium butyricum", "Microbiome modulation"],
      "intervention": ["Probiotics", "Proton pump inhibitors"]
    }
  },
  "43": {
    "reference_id": "43",
    "citation": "Terrisse et al., Cell Death Differ 2021",
    "title": "Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment",
    "year": 2021,
    "tags": {
      "treatment": ["Chemotherapy"],
      "cancer": ["Breast cancer"],
      "biology": ["Dysbiosis", "Treatment toxicity"],
      "intervention": []
    }
  },
  "45": {
    "reference_id": "45",
    "citation": "Zhang et al., Theranostics 2021",
    "title": "Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from CRC patients",
    "year": 2021,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade"],
      "cancer": ["CRC", "Preclinical tumor models"],
      "biology": ["Butyrate production", "Microbiome modulation"],
      "intervention": ["Prebiotics", "Pectin"]
    }
  },
  "48": {
    "reference_id": "48",
    "citation": "Dizman et al., Nat Med 2022",
    "title": "Nivolumab plus ipilimumab with or without live bacterial supplementation (CBM588) in metastatic RCC: a randomized phase 1 trial",
    "year": 2022,
    "tags": {
      "treatment": ["PD-1/PD-L1 Blockade", "CTLA-4 Blockade"],
      "cancer": ["RCC"],
      "biology": ["Clostridium butyricum", "Microbiome modulation"],
      "intervention": ["Probiotics", "Live bacterial supplementation"]
    }
  }
}



